Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aktis Oncology
Biotech
Why biotech IPOs are back for 2026
Whisper it, but we may finally be seeing the IPO window reopening in 2026.
James Waldron
Feb 13, 2026 3:30am
Radiopharma-focused Aktis bring in $318M via upsized IPO
Jan 9, 2026 4:52am
Aktis aims for $209M windfall from 1st biotech IPO of 2026
Jan 5, 2026 9:30am
Big Pharma-backed Aktis plans IPO to fund radiopharma trials
Dec 22, 2025 8:55am
Big Pharma backers return for Aktis' $175M series B
Sep 30, 2024 8:00am
Lilly pays Aktis $60M to further dial into radiopharma signal
May 21, 2024 8:50am
